VEGFA and neoplasm: Some authors have suggested that the multikinase inhibitor, lenvatinib, mainly used in combination with programmed cell death protein (PD)-1 inhibitors, potentiates antitumor activity and overcomes resistance to ICI by inhibiting vascular endothelial growth factor (VEGF) and fibroblast growth factor receptors and shifting the tumor microenvironment to an immune-stimulatory state.8-13